Candel Therapeutics Inc. (CADL) Dividend Safety Gauge & 10-Year DRIP Compounder

Per the Roarable RQD rating, CADL scores 34 out of 100, earning a letter grade of E and the verdict label "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 4/20 (ROIC -35%; FCF yield -5.88%), the weakest reading in the rating; Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 11/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).

For a prospective investor, the pillar profile points to a company whose operating economics are negative. Upside would have to come from a change in that cash engine, which the source data does not show in the reported periods. The balance sheet reads as middling rather than distressed, with cash reported at $119.7M in FY 2025, but the Piotroski F-Score of 2/9 signals weak fundamental quality. Insider and institutional signals are muted to weak. Valuation cannot be anchored to earnings, since P/E and EPS are not available in source data and net income is negative in every reported period. Any investment case here rests on future events not captured in the sources, which is the core reason the rating assigns a sell verdict.

Per the SEC financials, operating and net losses appear in all three periods, and margins are 0% gross, 0% operating, and 0% net in the market data. Per the Roarable RQD rating, ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, both per the Roarable forensic balance sheet pillar; Debt/Equity is 0.5. Reported cash is $119.7M for FY 2025, while FCF was $-38.9M, indicating ongoing cash consumption.

Per the recent news wire, six items reference CADL, all published within roughly 15 hours before the data timestamp, and each carries a YELLOW light and "MARKET WIRE" impact label. The headlines reference a stock price forecast from StockInvest.us, a TradingView estimates page, Yahoo Finance options chain coverage, a Simply Wall St note on analysts expecting breakeven, a MarketBeat short interest update dated October 2026, and a kalkine.ca list of biotech stocks to watch. These items are general market commentary; none describes a specific clinical, regulatory, or financing event in the provided text. Risk watch items drawn from the data are the short-interest reference and the negative cash flow. Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals.

• What clinical, regulatory, or partnership milestones are expected, and what is their timing? The source data does not describe a pipeline.
• What is the company's cash runway relative to the FY 2025 FCF of $-38.9M, and will new financing be needed?
• Why is the FY 2023 cash and debt position marked N/A, and what are the full balance sheet figures?
• What drove the year-over-year change in net loss between FY 2024 and FY 2025?
• What are the TTM earnings, forward estimates, and any analyst coverage, none of which appear in the source data?